Search

1 to 10 of 272
Sort by

Web Page
Immune Monitor - September 2020

A Message from the President Dear Colleagues, Our society continues its preparations toward our fully virtual 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) , scheduled for Nov. 9–14, 2020. Please take note that the SITC 2020 meeting registration fee has been waived...


Library Entry
Meet-the-Expert Webinar Series: Careers in Industry - Recorded Webinar and Presentation Slides

On September 1, 2020, leading experts in the cancer immunotherapy field discussed the various career paths and opportunities available in industry and answered questions from attendees . The recorded webinar and presentation slides are available below. Webinar Faculty: Moderator:...

2 attachments


Library Entry
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung

Lutathera is a 177 Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to...


Library Entry
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen receptor...


Library Entry
CD200 promotes immunosuppression in the pancreatic tumor microenvironment

A significant challenge to overcome in pancreatic ductal adenocarcinoma (PDAC) is the profound systemic immunosuppression that renders this disease non-responsive to immunotherapy. Supporting datas provide evidence that CD200, a regulator of myeloid cell activity, is expressed in the PDAC...


Library Entry
Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies

Intratumorous immunotherapy for cancer is currently thriving. The aim of such local strategy is to improve the therapeutic index of these treatments, for higher on-target/on-tumor activity and less on-target/off-tumor adverse events. Strategies allowing for slow release of anti-CTLA4 in the...


Library Entry
Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages

Macrophages play pivotal roles in tumor progression and the response to anticancer therapies, including radiotherapy (RT). Dual oxidase (DUOX) 1 is a transmembrane enzyme that plays a critical role in oxidant generation. The authors conclude that their data indicates that DUOX1 is a new target...


Library Entry
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Loss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents as shown in colon cancer. However, biologic significance and relevance to I/O in metastatic clear cell RCC (ccRCC) are unknown. The...


Library Entry
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and...


Library Entry
Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets

Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow. While recent advances in treatment for MM have improved patient outcomes, the 5-year survival rate remains ~50%. A better understanding of the MM cell surface proteome could facilitate...